Allo HSCT for adolescents and adults with PID has previously been avoided due to severe TRM and poor outcomes. We report the outcome of 34 consecutive patients undergoing RI Allo HSCT for PID, with a median age of 22 years (range 12-50) at transplant. 24 were 18 years at transplant. Diagnoses included X-CGD (n511), AR-CGD (n53), variant CGD with Crohn's (n51), CVID (one with T-NHL, one with HLH) (n54), autoimmune LPD (Fas mutation in one) (n52), X-linked LPD (n51), DCML deficiency (one confirmed Gata2 mutation) (n52), common gamma chain SCID (n51), undefined SCID with atypical HL and DLBCL (n51), NK deficiency (n51), AR IL12rec beta deficiency (n51), CD27 deficiency with HL and DLBCL (n51), XIAP with Crohn's and HLH (n51), Rag2 mutation with red cell aplasia (n51). Also included were severe JIA (n52) and refractory unclassified autoinflammatory syndrome (n51). Donors were MUD (n516), 1Ag MMUD (n56), matched sibs (n511) and a 10/10 paternal donor. Stem cell source was BM (n510) or PBSC (n524). RI conditioning regimens were Fludarabine, Melphalan, Alemtuzumab (n521), Fludarabine, Bulsulphan, Alemtuzumab (n59) or Fludarabine, Busulphan, ATG (n54). With a median follow up of 35 months (range: 2m to 10yrs 9m), the estimated overall survival is 91% at 1 year and 88% at 3 years, with no deaths observed beyond 28m posttransplant. Allo HSCT is well tolerated in this patient group and should be considered as an alternative therapeutic option in PID patients not transplanted in childhood where an appropriate donor is available. Triggers for referral include life-threatening infections, malignancy and refractory disease. Background: Type I interferon (IFN-1, IFN-alpha/beta) is a fundamental antiviral defence mechanism. Mouse models have been pivotal to understanding the role of IFN-1 in immunity, although validation of these findings in humans has been limited. Aim: We investigated the molecular basis of viral susceptibility in a previously healthy child with fatal encephalitis after inoculation of the live attenuated measles, mumps, and rubella (MMR) vaccine. Methods: We employed targeted candidate gene resequencing, together with in vitro assays of interferon signaling and response, and control of attenuated and wild-type viral replication in primary fibroblasts. We used lentiviral transduction to reconstitute patient cells.
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Background: Current management of patients that require immunoglobulin therapy is based on clinical judgement and expertise. To support healthcare professionals treating these patients, we propose a new Immunoglobulin Patient Evaluation Tool (IgPET) to assist assessment of patients' ongoing suitability for immunoglobulin treatment and provide an audit trail for these decisions. Using a set of auditable questions, based on patients' lifestyle, circumstances and diagnosis, this tool helps provide a standardised approach and addresses Key Performance Indicators for the National Immunoglobulin Database to ensure continued immunoglobulin supply and patient care. Methods: IgPET is designed to capture a patient's ability to self-administer immunoglobulin. Patient suitability for home therapy is assessed by their treatment history, age, distance from home to treatment centre, ability/willingness to self-administer and personal support network. The most suitable immunoglobulin administration method/frequency is also considered by recording: patient's immunoglobulin treatment status; feelings about infusing versus injecting; attitude towards using needles; confidence in infusion/injection technique; language/learning/manual dexterity/sight difficulties; infusion volume/multiple treatment site requirement; infusion frequency; known treatment adherence issues; practical problems or time issues with set-up/infusion; and lifestyle. Guidance can then be given on each patient's suitability for home therapy and the method/frequency of immunoglobulin administration. Results and Conclusions: Once implemented, IgPET should be used periodically throughout the patient's treatment journey to support provision of individualised therapy; it should not replace professional judgement but could aid training and decision making whilst capturing information for the purpose of clinical governance and audit. Background: Copy number variation (CNV) calling methods such as ExomeDepth enable the identification of CNVs by whole exome sequencing (WES). This facilitates detection of gene alterations for which routine Sanger sequencing analysis is not suitable, such as large heterozygous deletions. We detected by WES heterozygous single-or multi-exon deletions in IL7R, a known disease gene for autosomal recessive T-B1NK1 severe combined immunodeficiency (SCID). Methods: We analysed eleven patients with T-B1NK1SCID from seven families by WES using Agilent SureSelect XT exome enrichment and Illumina HiSeq2000 deep sequencing. GATK was used to detect SNVs and INDELs, and detection of CNVs was achieved with ExomeDepth.
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Results: Homozygous loss-of-function mutations in CD3E, CD3D and IL7R were detected in four patients. WES sequencing of patients from the remaining four kindreds revealed a heterozygous deletion of one or three exons of IL7R, coexisting with a heterozygous splice site or nonsense mutation elsewhere in the same gene. The deletion breakpoints were determined by Sanger sequencing in two patients, confirming the WES finding of exon 3 or exon 2-4 hemizygosity, respectively. Even though due to unavailability of parental DNA we could not confirm compound heterozygosity, the apposite phenotypes of the patients suggest that the IL7R mutations found here are biallelic. In our centre, as many as 39% of T-B1NK1SCID patients had such compound heterozygous IL7R deletions. Conclusions: We show that heterozygous IL7R exon deletions are common in T-B1NK1SCID, and are detectable by WES. Compound heterozygous IL7R deletions should be considered if Sanger sequencing fails to detect biallelic mutations. Background: Anti-cytokine autoantibodies (ACAAs) are pathogenic in a handful of rare immunodeficiencies. However, the prevalence and significance of other ACAAs across immunodeficiencies have not yet been described. Aim: We sought to profile ACAAs in a diverse cohort of serum samples from patients with immunodeficiency and assess the sensitivity and specificity of protein microarrays for ACAA identification and discovery. Methods: Highly multiplexed protein microarrays were designed and fabricated. Blinded serum samples from a cohort of 58 patients with immunodeficiency and healthy control subjects were used to probe microarrays. Unsupervised hierarchical clustering was used to identify clusters of reactivity, and after unblinding, significance analysis of microarrays was used to identify disease-specific autoantibodies. A bead-based assay was used to validate protein microarray results. Blocking activity of serum containing ACAAs was measured in vitro.
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Results: Protein microarrays were highly sensitive and specific for the detection of ACAAs in patients with autoimmune polyendocrine syndrome type I and pulmonary alveolar proteinosis, detecting ACAA levels consistent with those in the published literature. Protein microarray results were validated by using an independent bead-based assay.
To confirm the functional significance of these ACAAs, we tested and confirmed the blocking activity of select ACAAs in vitro. Conclusion: Protein microarrays are a powerful tool for ACAA detection and discovery, and they hold promise as a diagnostic for the evaluation and monitoring of clinical immunodeficiency Background: Evaluation of Salmonella typhi(Typhim TM ) antibody production could be useful for diagnosis of primary immunodeficiency (PID). Methods: We measured simultaneously at baseline and 1 month post-vaccination, the specific Ab response to purified Vi-polysaccharide (anti-Vi) antigens from Salmonella typhi (Typhim TM ), antibody protein diphtheria-tetanus(DT TM ), and Pneumococcal Capsular Polysaccharide (PCP)-specific antibody (Pneumo23 TM ) by specific ELISAs (The Binding Site,UK) in a cohort of patients with RI from one medical center. Collected 14 adult patients: Common Variable Immunodeficiency (CVID) n56, IgA deficiency (IgAD)n51; recurrent respiratory tract infection (RRTI) n54; recurrent urine tract infection (RUTI)n53 without known PID. We used three-fold increase to define normal Ab response to PS(Ratio:3x)showed in healthy patients (HC) (Ferry,Clin.Exp.Immunol,2004) .
Results: Anti-Vi responses (RatioTyphi:3x) were normal in CVID 33%(n52), IgAD 100% (n51), in RRTI 75% (n53) and in RUTI 100%(n53). The results for PCP production were the same of anti-Vi responses.
Concerning anti-DT responses (Ratio DF:3x) was CVID 33%(n52); IgAD 100%(n51); RRTI 50% (n52) and RUTI 33% (n51). Using ratioTyphi:10x (Sanchez-Ramon, submitted manuscript), which is the normal range production in HC, we observed: no patients CVID or RRTI produced normal anti-Vi and only one RUTI and other IgAD. In one patient either CVID on immunoglobulin (IvIg), we tested the absence of responses to anti-Vi,while anti-PCP titre and anti-DT could be due to the preparation. Discussion: The evaluation of specific Ab response to Vi-PS antigen could represent a complementary assay for the diagnosis and correct treatment of anti-ViAb production deficiency in RI patients. Anti-Vi could be a useful vaccine for the evaluation of in vitro Ab responses in patients with suspected immune deficiency on IvIg.
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Naturally Occurring Common-Antigen Antibody Levels And Immune Status Measurement Antony Parker; David Taylor; Dawn Sims; Alexander Cook; Stephen Harding; Gregg Wallace
The Binding Site Group Ltd
Background: Naturally occurring common-antigen antibodies (CaAb) are raised in response to infection or environmental exposure rather than vaccination and are likely to be present in healthy individuals due to continuous exposure to common antigens. Aim: Determine whether CaAb activities could be used as markers of antibody deficiency.
Methods: Enzyme immunoassays (EIA) to detect CaAb IgG and IgM against 2 bacterial, 1 fungal and 2 viral antigens were developed and optimised. Serum samples from primary (primary antibody deficiency (PAD; n520) and common variable immunodeficiency (CVID; n520)) and secondary immunodeficiency (multiple myeloma; MM, n520) patients were analysed and compared to healthy controls (n553).
Results: CaAb IgG and IgM levels were detected in healthy adult controls for all 5 specificities. There was a weak correlation between the different IgG specificities. However, the IgM values were clearly positively correlated (Spearman's Rho 0.66 to 0.84). IgG subclass analysis showed an IgG2 bias (>76% of total IgG) towards polysaccharide antigens. Correlation between total serum IgG and IgG CaAbs were weak (Rho 20.074 to 0.457), but somewhat higher (0.602 to 0.775) for total IgM. 9/10 CaAb IgG and IgM activity levels were significantly reduced in the three independent antibody deficient populations compared to controls (Mann-Whitney U, all p<0.02). Interestingly CMV IgG levels were not suppressed. Correlations between CaAbs and total serum immunoglobulins in immunodeficient patients were moderate for IgM but weak for IgG.
Conclusion:
Our results indicate that measurement of CaAbs can differentiate between a normal and suppressed humoral immune system and are relatively independent of total immunoglobulin concentration. Background: Polyarteritis nodosa (PAN) is a systemic vasculitis characterised by non-granulomatous necrotising inflammatory lesions of small-and medium-sized arteries. In most cases no underlying cause is identified and mortality is high. Adenosine deaminase 2 (ADA2) deficiency was recently described as the first genetic basis for PAN. ADA2 is a myeloid-derived growth factor found in plasma, and plays a key role in peripheral immune regulation including prevention of endothelial cell damage. We describe a rare case of ADA2 deficiency presenting with paediatric-onset fevers, vasculitis, strokes, and immunodeficiency in the second child of two unrelated Caucasian parents. Background: Warts, hypogammaglobulinaemia, infections and myelokathesis (WHIM) syndrome is a rare primary immunodeficiency clinically characterised by childhood onset infections from bacteria, viruses and fungi. It is caused by a gain-of-function mutation in the gene CXCR4.
P03 ADENOSINE DEAMINASE 2 (ADA2) DEFICIENCY -INSIGHTS INTO VASCULAR AND SYSTEMIC INFLAMMATION
Resultant over activation of the chemokine receptor CXCR4 causes retention of neutrophils and lymphocytes within the bone marrow. As a result of this many functions of the immune system are impaired.
Aim: We present a patient with WHIM syndrome due to heterozygous CXCR4 R334X mutation who was treated with a CXCR4 antagonist; plerixafor. Methods: A 47yr old female with a background of childhood liver abscess, bronchiectasis, warts and mycobacterial chest infections was identified to be CXCR4 R334X heterozygous. She had been neutropenic and lymphopenic since childhood and was unresponsive to polysaccharide vaccines with normal total immunoglobulins. Treatment was commenced with plerixafor 0.01mg/ kg BD for 3 months. Results: Plerixafor resulted in an increase of peripheral blood neutrophils and lymphocytes within 3hrs of the 1st dose. T, B and NK cells increased and then declined prior to the next dose of plerixafor. The patient had no infections during the treatment and stopped IVIG and prophylactic antibiotics. Unfortunately the patient suffered meningitic headaches related to plerixafor, with no biochemical inflammatory response, but declined lumbar puncture. Conclusion: Plerixafor presents a targeted treatment for-WHIM syndrome and demonstrates the potential therapeutic benefits of a molecular diagnosis. This treatment is an example of genomic and personalised medicine. Personalised medicine raises health economic issues with the expense of molecular diagnostics and modern precision therapeutics. /kg CD341PBSC from 10/10 MUD after reduced-intensity conditioning (treosulfan, fludarabine, alemtuzumab), with cyclosporine and mycophenolate mofetil GvHD prophylaxis, uneventful engraftment (day116; remains 100% donor chimaerism) followed by transient, steroid-responsive acute grade II skin GvHD. Seven months post-HSCT off all immunosuppression and well. Conclusion: Further follow up is required, but this case shows that HSCT may be a good option for patients with severe immunodeficiency due to STAT1-GOF mutation. A male child presented at 8 weeks with an erythematous annular rash on his limbs. He was clinically well and although the rash settled partially, it continued to flare intermittently. At 16 weeks he re-presented with vomiting and diarrhoea. The rash was quiet. On admission he was dehydrated and anaemic (Hb 45 mg/L) with renal impairment (urea 33 mmol/L, creatinine 585 umol/L). Serology and stool culture for E. Coli 0157 was negative. Atypical Haemolytic Uraemic Syndrome was diagnosed and Eculizumab commenced with good response. Subsequent genetic analysis for CFH, CFI, CD46, C3, CFB, DGKE (diacylglycerol kinase epsilon) was negative and Anti-Factor H antibodies negative. He was readmitted with haematuria at 12 months and was treated with plasma infusions and the Eculizumab increased to fortnightly. Immunology review at 15 months did not identify any significant history of infection. Immunoglobulins and specific antibodies to tetanus, Hib and Prevenar were normal (11/12 serotypes > 1.3ug/mL, 12/12 serotypes > 0.35ug/mL). However, he had a profound T cell lymphopenia affecting both CD41 and CD81 T cells (CD31 percentage 19%, absolute count 0.349 x 10 9 /L). Lymphocyte stimulation was normal with PHA but slightly reduced with candida compared to the control sample. ADA was present and T cell receptor V Beta repertoire normal but TRECs were zero. Whole exome sequencing identified a mutation in the LMX1B gene which causes Nail Patella syndrome. On review, his nails, patellae and elbows appeared normal. No iliac horns were present on x-ray. However, renal biopsy showed changes consistent with Nail Patella syndrome. The profound T cell lymphopenia remains unexplained. 
P06

UKPIN 2015 POSTERS
P15
UK).
Results: The median concentration pre-vaccination was 22 U/mL (range 0-270 U/mL) and post vaccination 53 U/mL (range 0-270 U/mL, 2 fold, p50.01). Using a cutoff ratio of 1 (pre/post vaccination concentration), Responders had a median 3 fold increase in concentration (range 1.3-21 fold) and Non-Responders a median of 1 fold (range 0-1 fold, P50.0002). 9/10 (90%) Responders reported no ear, nose or throat (ENT) infections whereas 2/5 (40%) Non Responders presented with ENT infections. Patients without ENT infection had higher pre vaccination 29 U/m (range 5-270 U/mL) vs. 2 U/mL (range 0-22 U/mL, P50.03) and higher post vaccination concentration 108 U/mL (range 27-270 U/ mL) vs. 9 U/mL (range 0-20 U/mL, p50.004) than those with infection. Conclusions: Individuals that have defective production of Pneumococcal IgM antibodies have a higher risk of ENT infection. Measurement of PCP IgM may aid identification of those antibody deficient patients at higher risk of infection. Background: In 2009 the UKPID Registry was established using the same platform as the ESID Registry. In the last 2 years there has been a move to simplify data entry and improve data quality, integrity and reliability. Following a successful pilot scheme, the new ESID design was introduced in June 2014 and will be launched in the UK in September 2015. Method: A UK version of the ESID Registry System (EERS), a Java web application developed by the ESID team in Freiburg, has been installed on servers at UCL. The new application, like the previous UKPID Registry, only requires a normal web browser to be accessed. Migration of data to the new system includes automatic verification checks to ensure diagnoses are in line with the ESID working criteria for clinical diagnosis as well as other validation Methods: to identify duplicate and incomplete entries. The new system has a single interface for data entry to simplify the documentation process. It also sends reminders to help keep entries up to date. The output of data has been simplified, offering users the option to download their entries as flat files or spreadsheets. Results: The new design comprises 3 levels; Level 1: demographic data and details of transplant and immunoglobulin replacement. Level 2: disease specific data. Level 3: available for dedicated research studies for a fixed time period. We offer an interactive presentation of the UKPID Registry for a demonstration of the new design and the opportunity to ask questions or discuss any issues. Background: Autosomal recessive (AR) severe combined immune deficiency with presence of B lymphocytes (B1SCID) occurs with mutations for Janus-associated tyrosine kinase 3 (JAK3) that associates with the yc chain of the IL2 receptor. Other defects in this signalling pathway are recognised. Clinical phenotype is indistinguishable from X-linked SCID. Reduced T-cell receptor excision circles (TRECS) on newborn screening may identify patients. Clinical Presentation: A three month old female with consanguineous parents presented with a soft tissue abscess on her leg and absent fever. Gram positive organisms were isolated. She re-presented with osteomyelitis at the cannula insertion site but remained systemically well. Total lymphocyte count was normal but profound T cell lymphopenia was seen. There was no previous history of recurrent infections. Scheduled immunisations including BCG and Rotavirus had been received. Her older sister had died in infancy from presumed Langerhans Histiocytosis. An EBV negative B-cell lymphoproliferative disease was identified at the site of suspected osteomyelitis with hepatosplenomegaly and pulmonary nodules. She received a bone marrow transplant but sadly died of veno-occlusive complications. Methods: Cell surface expression of TNFR1 by primary TRAPS dermal fibroblasts with three different mutations (T50M, C88R and the c.472 splice site mutation), plus three healthy control dermal fibroblasts (HC), was measured using immunofluorescence. Cells were stimulated with LPS (0.1ng/ml -10.0ng/ml), and expression of miR146a, miR-155 and pro-inflammatory cytokines (IL-6, IL-8 and IL-1b) quantified using qPCR/multiplex assays. Results: Cell surface expression of TNFR1 was absent, and there was downregulation of miR-146a and miR-155, in all TRAPS samples compared with HC. Although we observed variation in the overall levels of cytokines produced, for the T50M and C88R mutations, IL-6, IL-8, and IL-1b production peaked at lower doses of LPS (0.1ng/ml -1.0ng/ml) compared with HC. results for the c.472 mutation are currently being analysed.
P16
P17
Conclusions: This the first study to demonstrate absent surface expression of TNFR1 in dermal fibroblasts and reduced Background: X-linked agammaglobulinemia (XLA) is the prototypic B cell disorder, and typically presents with recurrent respiratory tract infections. In a minority of cases, however, it can present with neutropaenia. Aim and Methods: We describe two recently diagnosed cases of XLA that presented with both neutropenia and Pseudomonal soft-tissue infections. Results: Case 1: A 15 month old boy presented with fever and cellulitis in his groin. Neutrophil count at presentation was 0.1 x 10*9/L. Swabs from an ulcer at the site grew P aeruginosa. He responded well to systemic antibiotic therapy and replacement Ig therapy. His neutrophil count recovered quickly. He was subsequently found to be B-cell lymphopenic and panhypogammaglobulinemic. Case 2: A 13 month old boy presented with dactylitis and paronychia. He was neutropaenic at presentation (<0.1 x 10*9/L) and was found to be B-cell lymphopaenic and panhypogammaglobulinemic. Incision and drainage of abscess was undertaken and grew P. aeruginosa. gCSF was given to boost neutrophil production. He responded well to systemic antibiotics and surgical drainage, and is currently well on immunoglobulin replacement therapy. XLA was confirmed by genetic analysis in both cases. Conclusion: Neutropaenia and soft tissue infections are an uncommon but well described presentation of XLA. Lymphocyte subset phenotyping and serum immunoglobulin measurement should be undertaken in these circumstances, even without a positive family history. Increased susceptibility to recurrent respiratory tract infections and immune dysregulation often leads to pulmonary damage over time in patients with antibody deficiency which may cause changes in lung function. Immunoglobulin replacement is an effective treatment in reducing infections, however the benefits for lung function in the longer term are unclear. This outcomes review aims to ascertain whether adequate and timely treatment could prevent lung function decline relative to the healthy population norm. This was a retrospective cohort study of our outcomes database for adult patients with severe antibody deficiency receiving immunoglobulin replacement over a two year period at Barts Health NHS Trust, for whom lung function data was available. All available relative and absolute FEV1, FVC and KCO values were collected from both before and after the start of Ig-replacement for each patient. Factors related to antibody deficiency that might affect lung function were identified, including patient diagnosis, infection frequency, co-morbidities and medication history.
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After starting immunoglobulin replacement, with intensive surveillance and treatment of infection, in accordance with UKPIN recommendation, we found that there was no significant difference in the rate of decline of those with antibody deficiency compared to the average age-related rate of decline for the normal population. However, in patients with a low baseline lung function value, diagnostic delay was found to be significantly associated with poorer lung function. Other factors did not individually account for any significant effect but several groups of similar factors were significantly associated with a lower lung function. Introduction: Gain of function mutations in STAT3 have been linked to autoimmunity. To date, the phenotype described has been characterized by severe disease. Aim and Methods: We describe two kindred with members affected by STAT3 gain of function autoimmunity. Results: Kindred 1: P1 is a 9 year old girl with severe autoimmune enteropathy, arthritis, cytopenia, recurrent respiratory tract infections and lymphoproliferation characterized by hepatosplenomegaly and lymphadenopathy. Her cytopenias have remained problematic despite rituximab, IvIG, tacrolimus and sirolimus therapy. She is currently awaiting HSCT. Her brother also has lymphoproliferation and eczema and her mother developed autoimmune haemolytic anaemia in adulthood. All three members share the p.P715L mutation in STAT3. Kindred 2: P4 presented with enteropathy, arthritis and severe recalcitrant cytopenias. She underwent HSCT before succumbing to severe GvHD post-transplant. Her father has been treated for suspected sarcoidosis and in addition, has undergone treatment of renal malignancy. Her half-sister has severe keratoconjunctivitis, eczema and allergic rhinitis. All three share the same mutation in STAT3 (p. N420K). Conclusion: Autoimmunity due to STAT3 gain of function varies in severity, even within the same kindred. Consideration should be given to this diagnosis, particularly where family history suggests autosomal dominant inheritance. The new ESID design comprises 3 datasets. Level 1 is mandatory and contains basic demographic data plus details of immunoglobulin replacement and transplant. Level 2 contains details specific to the disease. Level 3 is for dedicated studies, which may be industry funded, to address specific questions and will have a fixed time frame. A level 3 project on the recently identified combined immunodeficiency Activated P13 Kinase Delta Syndrome (APDS) will be adopted from the ESID Registry.
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Results: This year the UKPID Registry has provided data for the NIHR rare diseases study into CVID and complement deficiencies and also for a Biotest project looking at the effectiveness of polyclonal immunoglobulin. The poster will give statistics on the prevalence of the main PID conditions, data on associated conditions such as bronchiectasis, granulomatous disease, malignancy and autoimmune conditions as well as trends in replacement therapy. It will also show the percentage of patients recruited per centre. Background: IqymuneV R is a new 10% sugar and sodiumfree highly-purified liquid LFB IVIg preparation with a low level of IgA. IqymuneV R manufacturing process was designed to optimize the tolerability profile. In order to assess its efficacy, pharmacokinectics (PK) and tolerability, a prospective, single-arm, multicentre European study was initiated in patients with PID. Methods: 62 patients (36 adults/26 paediatrics) with CVID (n542) or XLA (n520) were enrolled to receive 3-(n55) or 4-weekly (n557) infusions of 0.2 to 0.8 g/kg of IqymuneV R for 12 months. PK parameters were determined after the 8th infusion in 28 adults. Results: At study entry, 58 patients were receiving replacement therapy while 4 patients were na€ ıve to IgG administration. Mean age was 27.4 years [range 2-61]. Mean dose of IqymuneV R after the 6th infusion was 0.60 g/kg with mean serum IgG trough level of 7.76 g/L. The mean maximum infusion rate was 6.1 mL/kg/h. The flow rate was superior to 4 to 6 mL/kg/h for 21.1% infusions and to 6 to 8 mL/kg/h for 21.5%. Background: During intravenous immunoglobulin replacement therapy in primary immunodeficiency patients (PID), minor adverse events (chills, fever) occur frequently whilst major adverse events such as anaphylactic shock, thrombosis or haemolysis are rare. These associated risks are related to the impurities found in each product, and therefore vary, depending upon each IVIg's purification process. Methods: For 10% liquid IVIg (IqymuneV R ), LFB has designed a new purification process (IGNG) to eliminate or reduce impurities in order to reduce the occurrence of adverse events, whilst maintaining the structural and functional integrity of the immunoglobulin.
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Results: The design of the IGNG process induces a clear targeted contribution of each purification step. To prevent haemolysis, a dedicated affinity chromatography has been chosen as the best option for a robust process regarding the management of the level in anti-A and anti-B haemagglutinins. Other steps are included for aggregates reduction to avoid adverse events through complement activation (chills, fever) and for IgA reduction to avoid immune responses such anaphylactic shock in patients deficient in IgA. The contributive step to remove clotting factors was choosen for its robustness to reduce the risk of thrombogenic events. The designed and unique manufacturing IGNG process allows impurity reduction or elimination that has been translated into a good tolerance. Conclusion: The IGNG process, based on LFB's experience with ClairygV R , has been designed to elicit IqymuneV R with reproducible low content in impurities and improved tolerance. Background: Intravenous immunoglobulins (IVIg) are the gold standard therapy for PID. They are generally considered well tolerated, but adverse events may be induced by the impurities contained in some IVIg, related to the manufacturing process. Serious adverse events may have a significant impact on the management and the quality of life of PID patients. Methods: We have analyzed adverse events related to IVIg in PID patients based on published data between 1990 and 2015 in FDA workshop and Medline database. Results: The commonly reported adverse events were chills, fever, hypertension, hypotension in PID patients. Allergic reactions occured in 10% of patients with common variable immunodeficiency. Thromboembolic events after treatment with IVIg occurred in 2% of PID patients. Hemolysis could occur up to 5% of PID patients. These adverse events are induced by the impurities contained in IVIg such as IgA (allergic reaction), activated coagulation and contact activation factors (thromboembolic events) or anti-A and anti-B haemagglutinins (haemolysis). They may be significantly reduced with the optimization of the IVIg manufacturing process. Conclusion: A better understanding of the relationship between IVIg manufacturing process steps and the occurrence of the adverse events could permit to choose the most adequate IgIV according to the patient's profile.
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Acquired C1 Inhibitor Deficiency: Case Series Ariharan Anantharachagan; Sanja Ugrinovic; Dinakantha Kumararatne Clinical Immunology, Addenbrooke's Hospital Introduction: Here we present a case series of three patients between the ages of 50 to 70, initially presenting to their local hospital with just abdominal pain and subsequently developing cutaneous angioedema. All three patients were diagnosed with acquired C1 inhibitor deficiency (AAE). AAE is difficult to treat. A limited number of patients have achieved remission after treatment with Rituximab. Patients workup and management: In all three patients a small IgM paraprotein was detected by serum protein electrophoresis (SPE). Two of the patients were further diagnosed with a low grade Non-Hodgkin's lymphoma and one was diagnosed with a Monoclonal Gammopathy of Undetermined Significance (MGUS). Two patients with low grade Non-Hodgkin's lymphoma were treated with Rituximab. Their C1 inhibitor immunochemical and functional levels have normalised. They have remained free of abdominal pain and angioedema, without prophylactic treatment. Discussion: Treatment with Rituximab has been used only in limited number of AAE cases to date. Our experience adds to this published literature.
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Colonic Protothecosis Associated With Heterozygous Mutation In NCF-1 Sameer Bahal; Grant Hayman; Amolak Bansal; John Clark
Immunology, St Helier Hospital
A 30 year old lady, originally from Ghana, presented with chronic diarrhoea, hypoalbuminaemia and anaemia. Histological analysis of colonic biopsies revealed colitis with yeast-like bodies. These were identified at a Fungal Reference Laboratory as Prototheca sp, a spherical unicellular algae. Infections areusually caused by host immune impairment and treatment requires antifungal therapy with Amphotericin showing the best efficacy. The patient was investigated for an underlying immunodeficiency. Serum immunoglobulins, mannose binding lectin and lymphocyte subtypes were normal. A Dihydro-rhodamine (DHR) flow cytometryassay to assess neutrophil oxidative burst revealed impaired Neutrophil function, suggestive of autosomal recessive Chronic Granulomatous Disease (AR-CGD). The patient was found to be heterozygous for a mutation in NCF1 (gene for p47 phox). Homozygous mutations of this gene cause AR-CGD. However heterozygotes usually do not exhibit clinical symptoms and should not have abnormal neutrophil function. The relevance of this mutation is therefore unclear. The patient was treated with regular Intravenous Amphotericin via an indwelling catheter. However, therapy was complicated by drug induced hypokalaemia. Symptoms relapsed several times when attempts were made to withdraw Amphotericin. It was hypothesised that an underlying Inflammatory Bowel Disease was contributing by causing localised impairment of immune function. The patient was therefore started on Mesalazine with additional oral doxycycline. This allowed slow withdrawal of Amphotericin but several months later the patient relapsed.
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Investigations And Outcome Of Neutropenia In Children York M; Shackley F; Waruiru C Immunology Unit Sheffield Teaching Hospital, Sheffield Children's Hospital Background: Neutropenia is not infrequently seen in both paediatric immunology and haematology clinics. In the majority childrenthis resolves without complications following a period of observation and is often assumed to have been a post infectious phenomenon. Where neutropenia is recurrent, severe, persistent or associated with other clinical features investigation to identify causes including autoantibodies, gene defects associated with cyclical or congenital neutropenia or other immune deficiencies or metabolic conditions is indicated. Given the high rate of spontaneous resolution, identifying which children really need investigated can sometimes be difficult. Method: A retrospective case note review was carried out of children presenting to, or identified in, service as having moderate to severe neutorpenia (<1x10 6 ) over a 5 year period, was carried out. Information was collected on presentation, investigations, duration of neutropenia, infectious complication and use of prophylactic antibiotics or GCSF. Results: 82 children were identified. No cause was found in most patients ant the neutropenia resolved spontaneously. In some of the children with proven benign autoimmune neutropenia a possible infectious trigger was identified but in the majority this was not the case. 10 children required treatment with GCSF: 3 with ELA2 mutations, 2 with BArth syndrome and 2 with GSD1b. Conclusion: A joint pathway is being developed between our haematology and immunology teams around investigation and management of children with neutropenia not associated with use of chemotherapeutic agents. Introduction: Non-tuberculous mycobacterial (NTM) infections complicate 0.4-4.9% of haematopoietic stem cell transplants (HSCT). Patients with specific primary immunodeficiencies (PIDs), including severe combined immunodeficiency (SCID) and chronic granulomatous disease (CGD), are highly susceptible to NTM infection. Case Histories: We present 3 children who underwent HSCT for PID, whose post-transplant course was complicated by Mycobacterium chelonae bacteraemia and prolonged granulomatous inflammation. Patient 1 received an unconditioned HSCT for X-SCID. He developed acute graft versus host disease (GVHD) requiring corticosteroids treatment. 5 months post-HSCT, NTM was isolated from a blood culture and he was successfully treated with antibiotics. Following cessation of steroids and improved immune reconstitution, he developed a chronic cutaneous pyogranulomatous rash. Patient 2 received an unconditioned HSCT for X-SCID. Following immune reconstitution he developed prolonged fevers associated with multiple splenic lesions, and NTM bacteraemia was detected. Despite appropriate antibiotics, the fevers and the splenic lesions persisted, only resolving with the addition of corticosteroids. Patient 3 with CGD developed Mycobacterium chelonae sepsis pre-HSCT. His fevers resolved with antibiotics. Post-HSCT he required prolonged corticosteroid treatment for GVHD and developed intermittent acute pancreatitis caused by granulomatous lesions obstructing his pancreatic duct. 2 years post-HSCT the same NTM was isolated from blood cultures. In all cases Mycobacterium chelonae infection was isolated on extended culture, and in 2 cases on PCR. Conclusion: NTM disease should be considered as a cause of prolonged fever or unusual inflammatory complications in patients post-HSCT, particularly in patients with an underlying PID which predisposes to NTM. Gln225Argfs6) ) confirmed a diagnosis of WAS. At six months he developed spontaneous bruising around his right eye, with bilateral tender swellings affecting the zygoma and mandible. These lesions were painful and associated with fevers and a systemic inflammatory response. MRI imaging revealed osteolytic and sclerotic lesions, with additional foci in the ulnar and tibia. A bone biopsy confirmed a diagnosis of ICH. His symptoms and imaging improved steadily after commencing steroid therapy. He underwent a 10/10 matched unrelated bone marrow transplant 6 months later with full donor cell chimerism and remains clinically well without recurrence of cortical hyperostosis. Conclusion: This is the fourth reported case of WAS and Caffey disease in the literature, suggesting a mechanistic link. The association between these two rare diseases offers an opportunity to better understand the interaction between collagen dysfunction and dysregulated inflammation in bone disease. Introduction: A slowly developing oronasal communication in an adult patient is a rare finding. We present a case of palatal perforation due to downward extension of anti-neutrophil cytoplasmic antibodies (ANCA) negative granulomatosis with polyangiitis (GPA) from the nose and nasal septum. included regurgitation of fluid from the mouth to the nose followed by speech problems and difficulty chewing. The patient's past medical history consisted of: Common variable immune deficiency, Diamond-Blackfan anaemia, bronchiectasis, asthma and low-grade cervical dysplasia. She was being managed by a multidisciplinary team involving immunology, haematology, respiratory, gynaecology and ENT surgeons. The diagnosis of ANCA-negative GPA in this case based on the presence of granulomatous inflammation that has been confirmed on histopathological specimens and exclusion of other differential diagnoses. In addition, there was remarkable improvement in the inflammatory markers and symptoms following the commencement of immunosuppression with high dose steroids and cyclophosphamide. A simple prosthetic appliance provided by the oral surgery unit made a considerable improvement to the patient's quality of life in terms of oral function. Conclusion: The purpose of this report is to highlight a case that presented a significant diagnostic and therapeutic challenge. /L (31% of WBC). Immunodeficiency panel showed normal T, B and NK subset counts. B-cell immunophenotyping evidenced approximately 92% of B-cells in a single population: IgD1IgM1; the majority were CD271. Subsequent peripheral blood leucocyte immunophenotyping further characterised cells as CD51 monoclonal B-lymphocytes. The second patient had similar findings. They were referred to haematology and a diagnosis of monoclonal Blymphocytosis of undetermined significance (MBLUS) was made. No further investigations or therapies were initiated as the clones were small in both cases. Conclusions: Literature suggests that approximately 2% of the population have monoclonal B-lymphocytosis which, in some cases, can evolve into CLL. This is a teaching case which illustrates that CVID B-cell immunophenotyping can identify single cell populations which need to be further characterised by additional immunophenotyping in the haematology lab. This test has an added value in identifying causes of secondary hypogammaglobulinaemia with immune paresis.
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Background: Mutations in G6PC3 are typically associated with congenital neutropenia. We present the case of 2 siblings with a mutation in the G6PC3, associated with a novel phenotype of intermittent neutropenia and periodic fever syndrome (PFS). Case Presentation: The brothers have parents from a consanguineous marriage. At the age of 7 the older sibling developed severe oral ulceration, intermittent pyrexia, anal ulceration, abdominal pain, intermittent arthritis and conjunctivitis. The younger sibling has now started to manifest similar symptoms. Routine investigations revealed intermittent neutropenia (lowest count 0.42 x 109/l) and elevated CRP (highest 300mg/L). An oral biopsy showed granulomas, but further investigations refuted inflammatory bowel disease. Exhaustive investigations for infection, autoimmune diseases and PFS were unremarkable. Both have homozygous c130. C>T mutations in G6PC3 and are HLA-B51 positive. Compared to healthy controls their PBMCs produce significantly more IL-6 and IL-1b in response to LPS. Interestingly, this response is poorly attenuated by IL-10. The older sibling responds to corticosteroids but he failed colchicine and azathioprine. He is now responding well to adalimumab. Discussion: Oral ulcers and a cyclical neutropenia are the only clinical features previously described with c130. C>T mutation in G6PC3. The brothers also express HLA-B51 which is associated with Behcet's disease (BD). Some of their clinical features are in keeping with BD, however pyrexia and highly elevated CRP are infrequent manifestations. Furthermore BD associated oral ulcers tend to respond to azathioprine. It is therefore possible that the mutated G6PC3 may have a distinctive pro-inflammatory effect causing some of the PFS-like manifestations. Background: WHIM (warts, hypogammaglobuliamia, infection, and myelokathexis) syndrome is a rare immunodeficiency caused by heterozygous mutation in the CXCR4 gene. We describe the case of a 19 year old Caucasian man with recurrent infections, severe congenital neutropenia and myelokathexis who has a novel mutation in the CXCR4 gene. Case History: This gentleman was referred to the immunology clinic aged 10 years 11 months for further investigation of severe neutropenia. His first presentation was at the age of 5 months with peri-orbital cellulitis. Oral and intravenous antibiotics continued to be required for the treatment of recurrent infections; including cellulitis, ear infections, throat infections and recurrent pneumonia. He was not troubled with warts. He was otherwise a well boy with height and weight between the 25th and 50th centiles. Investigations: Investigations showed severe persistent neutropenia with neutrophil count ranging between 0.03X10 9 /L and 0.5x10 9 /L (reference 2-7.5) and lymphopenia with very low B cell count of 0.02 x 10 9 /L (reference 0.3-0.5). Serum immunoglobulin levels were initially normal but gradually dropped to IgG of 5.5 g/L (reference 6-16) and IgM of 0.46 g/L (reference 0.5-2). The bone marrow appearance was suggestive of myelokathexis. However, at that stage genetic testing of all exons and exonintron boundaries of the CXCR4, HAX1, ELANE/ELA2 and G6PC3 genes revealed no mutations. Whole exome sequencing performed in 2014 detected a heterozygous frame-shift mutation, c.654-C, p.T318fs320X in the CXCR4 gene (ENST00000241393, NM_003467.2). Results: Our cohort included 65 patients (M 53,F 12) with a mean age of 30.8years, X-linked CGD in 2/3 of cases, AR in 1/ 3; mean age at diagnosis 8.2years(0-41). Infectious complications were common in adulthood despite prophylaxis. Skin abscesses were most frequently seen, followed by liver abscesses, chest infections, lymphadenitis. Infections were a major source of morbidity, requiring multiple hospitalizations and surgery. IBD was more common in adulthood(30%) than childhood(23%), often presenting for the first time after transition. Surgical intervention was frequently required: multiple surgical drainage of perineal abscesses (6 patients), colectomy (5) or colostomy (3).The mean age at first major surgery was 30.4 years. Lung disease with CT changes was found in 34 patients out of 35 scanned, mostly consisting of nodules, fibrosis and bronchiectasis, with impaired lung functions in 14 out of 32 patients. Skin disease (acne, facial granulomatosis, DLE) was reported in 72% of patients. During follow-up 6 deaths occurred, 4 due to chronic pulmonary disease and 2 to infections. ). Prospective analysis revealed that at least two infusions (doses of approximately 0.4 g/kg) were required before patients tested positive for cAb. When samples were measured using the Galactomannan Enzyme-linked immunoassay (GM-EIA), results were strongly positive in certain products and negative in others; patient samples from those receiving relevant products were commonly above the threshold for positivity and revealed significant rises in GM-EIA index values from pre-infusion to post-infusion. Conclusions: Immunoglobulin products commonly transmit molecules which confound clinically important tests. Introduction: A majority of patients presenting with Pneumocystis jirovecii pneumonia (PJP) have an absolute CD4 T lymphocyte count <200/lL. PJP is becoming increasingly common in non-HIV patients due to frequent use of immunosuppressive agents. Infection in patients with chronic lymphocytic leukaemia (CLL) untreated with fludarabin is rare, although clinically relevant CD4 T-cell depletion can occur in longstanding CLL without prior treatment with purine analogues.We present a case of PJP in a patient with untreated CLL & a normal absolute CD4 positive T cell count. Case Report: A 66-year old male patient was referred to immunology whilst an inpatient in a high dependency The poster will describe how joint working between nursing and psychology supported a patient with needle phobia on subcutaneous immunoglobulin home therapy. Presentation, referral pathway and treatment plan will be detailed. Over the course of therapy, preparation and infusion time was reduced from 4 hours per week to just 1 hour a week.
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Other gains included a reduction in anxiety, depression and fatigue, increased engagement in daily life through more hours outside the home, and the patient feeling better able to manage their condition.
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The Background: Congenital neutropenia (CN) is a rare, inherited condition and affected individuals are susceptible to severe/recurrent bacterial infections. Treatment focuses on prevention of infections and historically includes antimicrobial prophylaxis and granulocyte-colony-stimulating factor (G-CSF). We report the first case of subcutaneous immunoglobulin (SCIg) manual push treatment in a child with CN, atrial septal defect (ASD) and pulmonary hypertension. Methods: After birth, immediate intubation/ventilation were required and, prior to home discharge on oxygen, G-CSF treatment was commenced for neutropenia. At 4-months, the child was hospitalised with bronchiolitis and pneumonia, ventilated and prescribed prophylactic acyclovir/co-trimoxazole. After discharge on oxygen (0.2 L/min), several re-admissions for recurrent respiratory failure were required over the next months. During a re-admission requiring ventilation, chest CT showed: large ASD with enlarged right atrium/ventricle; diffuse air-space consolidation in posterior segments of left/lower lobe; and bronchomalacia. Five months later, re-admission with intubation/ ventilation was required due to coryzal illness, increased breathing effort/oxygen requirements and low IgG level (2.95 g/L). Co-amoxiclav/co-trimoxazole were given. Chest X-ray confirmed right lower lobe collapse/shadowing of both upper lobes. Low lymphocyte/neutrophil levels were also observed. Intravenous immunoglobulin was implemented at 1 g/kg; however, SCIg manual push (1 g given into 2 sites over 5 minutes) was commenced in accordance with the family's wishes. Results: At 5-month follow-up, chest X-ray showed hyperexpansion and chronic changes but no consolidation/collapse. Since commencing weekly SCIg manual push the patient has visited hospital once, due to probable viral infection/parental anxiety. Conclusions: SCIg manual push is efficacious and welltolerated in paediatric patients with CN. Background: CFSE as a measure of lymphocyte proliferation is increasingly used in the laboratory setting both to avoid the use of radioactivity (e.g. triated thymidine) and to provide additional data on the characteristics of cell division.
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Aim: To review quantitative and qualitative assessment of lymphocyte proliferation by CFSE in Primary Immunodeficiency. Methods: We reviewed 387 requests over a 5 year period. Of these 228 (59%) were appropriately requested to investigate immune deficiency and were evaluable. Results: For PHA stimulation assay failure occurred in 5.3% of cases and for CD3/28 stimulation in 12%. Proliferation was grouped for analysis as good (59% PHA, 50% CD3/28), normal (23% PHA, 24% CD3/28), poor (11% PHA, 3/5% CD3/28) or absent (1.8% PHA, 0.9% CD3/28. Conclusions: The causes of assay failure, criterion for qualitative assessment and clinical associations with poor proliferation are presented.
